Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Rezafungin

Rezafungin

Basic information Safety Supplier Related

Rezafungin Basic information

Product Name:
Rezafungin
Synonyms:
  • Rezafungin
  • SP-3025
  • long-lasting,infection,SP3025,CD 101,antifungal,Fungal,inhibit,echinocandin,CD-101,Inhibitor,Rezafungin,SP 3025
  • Echinocandin B, 1-[(4R,5R)-4-hydroxy-N2-[[4′′-(pentyloxy)[1,1′:4′,1′′-terphenyl]-4-yl]carbonyl]-5-[2-(trimethylammonio)ethoxy]-L-ornithine]-4-[(4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-allothreonine]-
  • Bexagliflozin Impurity 38
CAS:
1396640-59-7
MF:
C63H85N8O17
MW:
1226.41
Mol File:
1396640-59-7.mol
More
Less

Rezafungin Chemical Properties

InChIKey
LNFCWEXGZIEGJW-WIQSWMFQNA-O
More
Less

Rezafungin Usage And Synthesis

Description

Rezafungin is a novel, once-weekly antifungal being developed for the treatment and prevention of serious fungal infections.Rezafungin is a member of the echinocandin class of drugs. Echinocandins are considered the safest antifungal drugs available and are suggested by the Infectious Disease Society of America (IDSA) as first-line treatment for fungal infections.

Uses

Rezafungin (CD-101) is a second generation echinocandin with a similar spectrum and mechanism of action. Along with fosmanogepix, ibrexafungerp, olorofim, and opelconazole, rezafungin heralds a new era in the treatment of fungal infections.

Side effects

Adverse effects associated with the use of Rezzayo may include, but are not limited to, the following: hypokalemia, pyrexia, diarrhea, anemia, vomiting, nausea, hypomagnesemia, abdominal pain, constipation, and hypophosphatemia.

Mechanism of action

Rezafungin is a semi-synthetic echinocandin. Rezafungin inhibits the 1,3-B-D-glucan synthase enzyme complex, which is present in fungal cell walls but not in mammalian cells. This results in the inhibition of the formation of 1,3-B-D-glucan, an essential component of the fungal cell wall of many fungi, including Candida species (spp.). Inhibition of 1,3-B-D-glucan synthesis results in concentration-dependent in vitro fungicidal activity against Candida spp., however, the clinical significance of this activity is unknown.

References

[1] Syed, Yahiya Y. “Rezafungin: First Approval.” Drugs 83 9 (2023): 833–840.
[2] Desnos-Ollivier, Marie and Fanny Lanternier. “New antifungals development: rezafungin in candidiasis treatment.” Lancet Infectious Diseases 22 3 (2023).

RezafunginSupplier

Shanghai Minkai Biological Technology Co., Ltd Gold
Tel
021-021-52919136 17315815539
Email
2804155403@qq.com
Zhejiang Huida Biotech Co., LTD Gold
Tel
0571-0571-89903882 15990081639
Email
sunshixuan@huidabiotech.com
Zhejiang Huida Biotech Co., LTD Gold
Tel
0571-89903882 13626641628
Email
jiangnan@huidabiotech.com
Taizhou Nanfeng Pharmaceutical Research Institute Gold
Tel
18616377689
Email
nanfengdrug@163.com
T&W GROUP
Tel
021-61551611 13296011611
Email
contact@trustwe.com